1 completed, 1 unknown. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Azacytidine: new trials by email Literature Review of Azacytidine trials Research Report on Azacytidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML Visilizumab - Immunotherapy, Refractory Leukemia | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 30 | 2021-05-01 | 2021-12-03 |
| Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Azacitidine, Cytarabine, Decitabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 76 | 2018-02-02 | 2025-01-16 |
Leukemia, Myeloid, Acute (2) · GATA2 Deficiency (1) · Leukemia (1) · Myelodysplastic Syndromes (1) · Recurrence (1)
National Cancer Institute (NCI) (1) · The First Affiliated Hospital of Soochow University (1)
China (1) · United States (1)
Han Yue, Ph.D (1) · Laura C Michaelis (1)
U10CA180888 (1)